follow us

follow us

Speakers

  1. Pharmacovigilance World 2024
  2. Speakers
  3. David Gillen

David Gillen


Chief Medical Officer - Norgine



David is the Chief Medical Officer at Norgine and has been in post since May 2022. David qualified in Medicine, Physiology and Clinical Pharmacology from St. Mary’s Hospital (Imperial College of Science, Technology and Medicine) in 1992. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Cardiology and General Medicine and joined Pfizer Global Research and Development in Sandwich in 1999. After leaving Pfizer David held the role of Head of International Medical Affairs for Gilead Sciences. In 2011 he then moved to work at Celgene where he was Head of Drug Safety and Risk Management for EMEA / APAC for Celgene Ltd. In addition David acted as the QPPV for Celgene’s Pharmacovigilance System in Europe. In 2016 David moved to become Vice President of International Medical Affairs at Vertex. In 2019, he was given additional responsibility supervising the whole International Global Development and Medical Affairs function for Vertex. In 2022 David became CMO of Norgine based in London. David has served on the Innovation sub- committee of the ABPI (Initiating the ABPI Real – World data project), represented Industry on the NICE Appeal Panel and was a member of the important RCP working party looking at the relationship between Industry, Academic Medicine and the NHS. David is a visiting Lecturer at Queens University Belfast and Kings College London.



David Gillen

Sessions


  • Wednesday - September 11, 2024 - 13:50

    Pharmacoepidemiology and Real-World Evidence (RWE) Generation

    • How pharmacoepidemiology methodologies contribute to the generation of real-world evidence, including observational studies, data analysis, and the evaluation of drug safety and effectiveness in diverse patient populations
    • The practical applications of real-world evidence in informing regulatory decisions, clinical guidelines, and healthcare policies, and its role in enhancing patient outcomes and reducing healthcare costs
    • The challenges in utilizing real-world evidence, such as data quality, bias, and standardization, and discussing emerging trends and innovations in pharmacoepidemiology and RWE generation for evidence-based healthcare
      Presentation

  • Wednesday - September 11, 2024 - 14:15

    Panel Discussion - Integrated Drug Safety Surveillance Systems: Fostering Collaboration for Enhanced Pharmacovigilance

    • Assessing the benefits and hurdles in forming a network that includes pharmaceutical companies, healthcare providers, and regulatory bodies for improved drug safety monitoring
    • Discussing strategies for standardizing data collection, reporting, and analysis across various organizations to ensure consistent and reliable pharmacovigilance
    • Investigating how AI, blockchain, and big data are transforming ADR detection and analysis, increasing the efficiency and precision of pharmacovigilance
    • Emphasizing the need for effective communication and collaboration among patients, healthcare providers, and regulatory bodies to establish a trust-based pharmacovigilance system
    • Detailing best practices and essential factors for successful collaborative pharmacovigilance, with a focus on regulatory compliance, data privacy, and cross-sector cooperation

 

Stay Informed

Subscribe today to receive news on latest updates,
offers and upcoming conferences via email

For general conference and registration enquires please contact the below email id or fill out the form

Enquire now